Tyvyt
(sintilimab)Phase 3Monoclonal antibody
Innovent Biologics (Suzhou) Co. Ltd.Sintilimab is used to treat certain types of cancer, particularly non-small cell lung cancer and other solid tumors, by helping the immune system recognize and attack cancer cells.[1] Tyvyt is currently being investigated across 76 indications[3], with its most advanced program in Phase 3.[1]
Tyvyt is one of 1238 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 3.
76
Indications
312
Total Trials
98
Active Trials
1,237
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 76 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Duragesic
CCephalon
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Bisphosphonate
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma21 trials
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05617430·43 enrolled
Show 18 more trials
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05616390·30 enrolled
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06512467·30 enrolled
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Not yet recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 2/3·NCT07490262·680 enrolled
Non-Small Cell Lung Cancer13 trials
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer
Not yet recruiting·—·Phase 2·NCT06221462·30 enrolled
Show 10 more trials
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Not yet recruiting·—·Phase 2·NCT06198907·69 enrolled
Gastric Cancer12 trials
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05627414·30 enrolled
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06487715·42 enrolled
Show 9 more trials
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07263386·460 enrolled
Sintilimab9 trials
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07474103·49 enrolled
Show 6 more trials
Esophageal Squamous Cell Carcinoma8 trials
Show 5 more trials
79 more indications
Lung Cancer8 trials
Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer
Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04840758·39 enrolled
Show 5 more trials
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04836728·156 enrolled
Colorectal Cancer6 trials
Show 3 more trials
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
Unknown status·—·Phase 2·NCT04179084·30 enrolled
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07007767·32 enrolled
Esophageal Cancer5 trials
Show 2 more trials
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03946969·30 enrolled
Chemotherapy4 trials
Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT04882462·100 enrolled
Show 1 more trial
Adenocarcinoma4 trials
Cervical Cancer4 trials
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Not yet recruiting·—·Phase 2·NCT07088731·180 enrolled
Show 1 more trial
A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer
Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 2·NCT05105672·20 enrolled
Lymphoma4 trials
Nasopharyngeal Carcinoma4 trials
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT06680115·150 enrolled
Show 1 more trial
Locally-advanced Rectal Cancer4 trials
Pancreatic Cancer3 trials
Advanced NSCLC3 trials
Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03874000·43 enrolled
Advanced Solid Tumors3 trials
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05527821·36 enrolled
Bevacizumab3 trials
Intrahepatic Cholangiocarcinoma3 trials
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05251662·90 enrolled
Metastasis3 trials
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05524155·30 enrolled
Anti-PD-1 Antibody2 trials
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
Unknown status·—·Phase 2·NCT05461235·1 enrolled
Neoadjuvant Chemotherapy2 trials
Efficacy and Safety2 trials
Treatment2 trials
First-line Treatment2 trials
Head and Neck Squamous Cell Carcinoma2 trials
Neoadjuvant Therapy2 trials
Gastric Adenocarcinoma2 trials
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05594381·90 enrolled
Metastatic Colorectal Cancer2 trials
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05171660·446 enrolled
Central Nervous System Lymphoma2 trials
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04961515·19 enrolled
Unresectable2 trials
Chemoradiotherapy2 trials
Glioblastoma1 trial
Clinical Trial1 trial
PD-1antibody1 trial
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Active, not recruiting·—·N/A·NCT06357806·45 enrolled
Ovarian Cancer1 trial
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Completed·—·Phase 2·NCT03989336·84 enrolled
Pancreatic Carcinoma1 trial
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05627427·60 enrolled
Rectal Cancer1 trial
Thyroid Cancer1 trial
Hypofractionated Radiotherapy1 trial
Squamous Cell Carcinoma1 trial
Renal Cell Cancer1 trial
First Line Therapy1 trial
Appendix Carcinoma1 trial
Premalignant Lesion1 trial
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04065737·29 enrolled
Gastroesophageal Junction Adenocarcinoma1 trial
Advanced or Metastatic Solid Tumour1 trial
Safety and Efficacy1 trial
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
Unknown status·—·Phase 1·NCT04104074·20 enrolled
Cholangiocarcinoma1 trial
Advanced1 trial
Ovarian Clear Cell Carcinoma1 trial
Adjuvant Therapy1 trial
Drug Resistance1 trial
Endometrial Cancer1 trial
T Cell1 trial
Borderline Resectable1 trial
Advanced or Metastatic NSCLC1 trial
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
Unknown status·—·Phase 2·NCT04612673·33 enrolled
Becotatug Vedotin1 trial
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT07459296·266 enrolled
Stage IV NSCLC1 trial
Neuroendocrine Neoplasm1 trial
Malignant Tumors1 trial
Small Cell Lung Cancer1 trial
Concurrent Chemoradiotherapy1 trial
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06341595·40 enrolled
Epstein Barr Virus1 trial
Biliary Tract Cancer1 trial
Radiotherapy1 trial
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Recruiting·—·Phase 3·NCT07186621·286 enrolled
Surufatinib1 trial
Resistance1 trial
Soft Tissue Sarcoma1 trial
Cutaneous T-cell lymphoma1 trial
Head and Neck Tumors1 trial
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06240689·104 enrolled
Liver Cancer1 trial
Growth1 trial
Neoadjuvant Treatment1 trial
Neuroblastoma1 trial
Esophageal Adenocarcinoma1 trial
EBV-Positive DLBCL, Nos1 trial
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04181489·55 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sintilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details